Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease

Head and Neck

Volumn 32, Issue 9, 2010, Pages 1167-1172

  Erovic, Boban M ^a   Schopper, Christian ^a   Pammer, Johannes ^a   Vormittag, Laurenz ^a   Maleki, Amir ^a   Brunner, Markus ^a   Heiduschka, Gregor ^a   Grasl, Matthaeus Ch ^a   Thurnher, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

recurrence; salivary gland tumors; treatment modalities

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SALIVARY GLAND CARCINOMA; TUMOR CLASSIFICATION;

ADENOMA, PLEOMORPHIC; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, ADENOID CYSTIC; CARCINOMA, MUCOEPIDERMOID; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS, MINOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78349281514     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21312     Document Type: Article

References (22)

1. Lopes MA, Santos GC, Kowalski LP,. Multivariate analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 1998; 20: 699-706.
2. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA,. Stage as major long term outcome predictor in minor salivary gland carcinoma. Cancer 2000; 89: 1195-1204.
3. Seifert G, Sobin LH,. Histological typing of salivary gland tumours. World Health Organization International Histological Classification of Tumours, 2nd edition. New York: Springer-Verlag, 1991.
4. Anderson JN, Beenken SW, Crowe R, et al. Prognostic factors in minor salivary gland cancer. Head Neck 1995; 17: 480-486.
5. Beckhardt RN, Weber RS, Zane R, et al. Minor salivary gland tumors of the palate: clinical and pathological correlates of outcome. Laryngoscope 1995; 105: 1155-1160.
6. Loh KS, Barker E, Bruch G, et al. Prognostic factors in malignancy of the minor salivary glands. Head Neck 2009; 1: 58-63.
7. Bell RB, Dierks EJ, Homer L, Potter BE,. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005; 63: 917-928.
8. Chou C, Zhu G, Luo M, Xue G,. Carcinoma of the minor salivary glands: results of surgery and combined therapy. J Oral Maxillofac Surg 1996; 54: 448-453.
9. Garden A, Weber RS, Ang KK, Morrison WH, Matre BA, Peters LJ,. Postoperative radiation therapy for malignant tumors of minor salivary glands: outcome and patterns of failure. Cancer 1994; 73: 2563-2569.
10. Le QT, Birdwell S, Terris DJ, et al. Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 1999; 52: 165-171.
11. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR,. Management of minor salivary gland carcinomas. Int J Rad Oncol Biol Phys 1996; 35: 443-454.
12. Sadeghi A, Tran LM, Mark R, Sidrys J, Parker RG,. Minor salivary gland tumors of the head and neck: treatment strategies and prognosis. Am J Clin Oncol 1993; 16: 3-8.
13. Bradley PJ,. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 127-132.
14. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck 2004; 26: 681-692.
15. Le QT, Birdwell S, Terris DJ, et al. Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 1999; 52: 165-171.
16. Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R,. Major and minor salivary glands tumours. Crit Rev Oncol Hematol 2003; 45: 215-225.
17. Surakanti SG, Agulnik M,. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 2008; 35: 309-319.
18. Mehra R, Cohen RB,. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am 2008; 22: 1279-1295.
19. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients. Cancer 1991; 68: 1874-1877.
20. Jones AS, Phillips DE, Cook JA, Helliwell TR,. A randomized phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer 1993; 37: 112-124.
21. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91: 541-547.
22. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AH, Strong EW,. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg 1991; 162: 330-336.